Searched for
GLENMARK Q3
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Glenmark shares in focus after recall of 15 lakh bottles of ADHD drug in USGlenmark share price: The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark Pharm...
- Glenmark Pharma shares in focus as company swings back to profit in Q3Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previou...
- Glenmark Pharmaceuticals Q3 Results: PAT at Rs 348 crore versus YoY loss, revenue up 35%Glenmark Pharmaceuticals Q3 Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY...
- Glenmark Pharma Q2 Results: Co posts Rs 355 crore net profit on robust sales growthGlenmark Pharma reported Rs 340 crore net profit in Q2FY25 led by robust sales growth in India and Europe. The drugmaker reported a net los...
- Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 resultsShares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma repor...
- Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoYGlenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss ...
- Glenmark Q3 Results: Co reports net loss of Rs 351 cr on lower domestic salesTotal revenue from operations declined to Rs 2,507 crore as compared with Rs 3,100 crore in the year-ago period, Glenmark Pharma said in a ...
- Glenmark reports Rs 403 crore loss in Q4FY23For the fourth quarter of FY23, Glenmark’s consolidated revenue was at Rs. 3374 crore as against Rs.3019 crore in the same quarter of previ...
- Glenmark Q3 Results: Net profit jumps 21% YoY to Rs 291 croreIndia Business grew by 6.7% YoY to Rs. 1075 crore. North America revenues grew by 10.6% to Rs. 837 crore.Glenmark's Europe revenues rose 29...
- Glenmark Q2 Results: Net profit rises 1.4% YoY to Rs 278 croreRevenues rose 7.2% YoY to Rs 3,375 crore during Q2FY23 as against Rs 3,147 crore in Q2FY22
- Add Glenmark Pharmaceuticals, target price Rs 607: ICICI SecuritiesGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 14885.78 Crore) operating in ...
- Glenmark Q3 profit zooms 64% to Rs 191 crore; firm to raise $400 millionRevenue stood at Rs 2,735.56 crore against Rs 2,555.04 crore last year.
- Glenmark Q3 profit up 11% to Rs 116 croreConsolidated revenue stood at Rs 2,555.04 crore against Rs 2,203.66 crore in the year-ago period.
- Hold Glenmark Pharmaceuticals, Rs 530: EdelweissHold Glenmark Pharmaceuticals Ltd. at a price target of Rs 530.0 .
- Glenmark Pharmaceuticals dips nearly 7% on disappointing Q3 nosReacting to the weak numbers, shares of the company opened the day on a weak note and later lost 6.64 per cent to Rs 291.40 on the BSE.
- Glenmark Pharma Q3 net nearly halvesDrugmaker Glenmark Pharmaceuticals Ltd's quarterly profit nearly halved on heavy foreign exchange losses from overseas borrowings despite r...
Load More
